ICT

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jun 21, 2007 - BioSantePharmaceuticals, Inc. (AMEX:BPA) today provided comment on theWomen's Health Initiative (WHI) Coronary Artery Calcium Studypublished yesterday in The New England Journal of Medicine (NEJM).The study found that younger menopausal women (aged 50-59) whoreceived a standard dose of estrogen therapy had significantly lesscoronary artery...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented theresults of a study conducted by researchers at the University ofChicago and ApoCell at the 2007 annual meeting of the AmericanSociety of Clinical Oncology (ASCO) held in Chicago in early June.The study showed that ApoCell's advanced pharmacodynamic biomarkerassay technology provides reliable predictive data of clinicalrespon...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor responses and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

Study highlights importance of antiplatelet therapy compliance NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced results from an analysis of more than 7,000 patients fromits ARRIVE 1 and 2 registries, designed to assess the performanceof the TAXUS(R) Express2(TM) paclitaxel- eluting coronary stentsystem in "real-world" p...

Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments

Addiction can lead to hospitalization and drug withdrawal CHICAGO, May 15, 2007 /PRNewswire/ -- A new survey of hundredsof migraine patients and physicians commissioned by the NationalHeadache Foundation and conducted by Harris Interactive shows that20 percent of migraine patients are currently taking potentiallyaddictive medications that contain barbiturates or opioids and havenot been a...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ --Catalyst Pharmaceutical Partners, Inc. announced today positiveinitial, top-line results from a bioequivalence study demonstratingthat CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable andbioequivalent to Sabril Tablets, the version of vigabatrin marketedin Europe by Sanofi Aventis. These data potentially provide a basisfor...

Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform

HAMBURG, Germany, May 03, 2007 /PRNewswire/ -- At the April AACRAnnual Meeting, Indivumed presented data which provide a soundscientific basis for a new drug test-platform to predict drugresponse in patients. Tumor tissue-derived primary cell lines are currently the firstchoice for cancer drug testing. During their clonal selection andexpansion, however, their gene and protein expr...

New Data Shows Once a Day Lamictal XR is Effective in Treating Patients with Partial Seizures

Data Presented at the American Academy of Neurology Annual MeetingShow Approximately 50 Percent Reduction in Partial Seizures BOSTON, May 01, 2007 /PRNewswire/ -- Data from two clinicaltrials presented today at the American Academy of Neurology (AAN)meeting suggest that an investigational once daily extended releaseformulation of Lamictal(R) (lamotrigine) is effective as add-ontreatment i...

Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest

BOSTON--(BUSINESS WIRE)--Apr 26, 2007 - A new study published todayin the New England Journal of Medicine ("A National Survey ofPhysician-Industry Relationships") on the extent of doctor andpharmaceutical company relationships, highlights the need forprofession-wide and public policy reforms promoted by ThePrescription Project. The article concludes that the existing,voluntary PhRMA (Pharma...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

- Findings Published in Blood Highlight Millennium Leadership inPersonalized Medicine and Could Strengthen the Role of VELCADE asFoundation of Therapy in Broad Range of Multiple Myeloma Patients - CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ --Findings published in the April 15th issue of Blood show that ateam of researchers led by Millennium Pharmaceuticals, Inc. hasdiscovered...

New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia

Findings indicate early non-responders unlikely to subsequentlyrespond, have substantially more treatment costs, and may benefitfrom earlier change in treatment strategy COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/-- New data presented at the 2007 International Congress onSchizophrenia Research (ICOSR) suggest that antipsychotic drugresponse be assessed earlier than is p...

Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment

WAYNE, N.J., April 02, 2007 /PRNewswire/ -- Berlex, Inc., a U.S.affiliate of Bayer Schering Pharma AG, Germany, announced today theresults of a retrospective study demonstrating that the presence ofneutralizing antibodies (NAbs) that can develop in response toBetaseron(R) (interferon beta-1b) therapy did not predict clinicalresponse in patients with multiple sclerosis (MS).(1) The studyl...

Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results showthat elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), acardiovascular-specific inflammatory enzyme associated withunstable plaque that can lead to heart attack and stroke, isespecially predictive of heart disease risk in patients with themetabolic syndrome--a serious medical condition that affects nearly50 million Ame...